News
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that ...
Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Structure Therapeutics Inc. (NASDAQ:GPCR) showcased preclinical findings for ACCG-2671 and ...
Circio Holding ASA announced a live webcast to present its first half 2025 financial results and recent in vivo data for its circVec platform technology.
The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to responsible pain management.
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and ...
Angitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025 Provided by GlobeNewswire Aug 19, 2025, 11:30:00 AM ...
This adjustment follows the release of pivotal Phase 2 ARROS-1 data, which highlighted the drug’s superior performance compared to existing therapies.
Cross-functional data flow: Evaluates the smooth transfer of data between teams to support collaboration and is determined by tracking the number of successful data exchanges between different ...
Hosted on MSN21d
Billions Flow Into AI Data Centers Despite Environment Risks
Douglas McIntyre, Editor-in-Chief at Climate Crisis 24/7, explains how private equity and credit lenders are pouring billions into AI data centers, despite their massive energy consumption and ...
Structure Therapeutics Inc. (NASDAQ:GPCR) showcased preclinical findings for ACCG-2671 and GSBR-5595 in two late-breaking posters at the ADA 85th Scientific Sessions.
Some Kentucky water supplies were found to have high levels of "forever chemicals." Here’s what that means.
Approximately 19 million people globally die from cardiovascular disease each year. Merck’s presentations at ESC 2025 reflect the company’s ongoing research efforts aimed at improving outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results